Skip to main content
SpringerLink
Log in

Histopathology of Adult and Pediatric Glioblastoma

  • Chapter
  • First Online:
Precision Molecular Pathology of Glioblastoma

Part of the book series: Molecular Pathology Library ((MPLB))

Abstract

Glioblastomas (GBMs) are the most common overall malignant primary brain tumor, with 3.23 cases per 100,000 in the adult population. In children, they are much less common, with a reported incidence of 0.14 cases per 100,000. The prognosis of these high-grade tumors is typically poor and most patients succumb to their disease within a few years. Most of these tumors occur sporadically; although rare, GBMs can display familiar inheritance. Syndromes that are associated with GBM include Li-Fraumeni, L-2 hydroxyglutaric aciduria, Neurofibromatosis type 1, Ollier/Mafucci, and Turcot. This chapter summarizes the histopathologic features of all major GBM subtypes, as well as includes important clinical features of certain subtypes when relevant. Additionally, the expected histopathological features and subtypes of children, versus adults, versus syndrome-associated will be elucidated. Our goal is to assist the practicing pathologist in recognition and diagnosis of GBM, including intraoperatively, in order to aid neurosurgeons and neuro-oncologists in treatment and patient care decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Burger PC, Scheithauer BW, editors. Neuropathology. Salt Lake City, UT: Amirsys; 2012. 800 p. (Diagnostic pathology).

    Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. Weltgesundheitsorganisation. WHO classification of tumours of the central nervous system. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2016. 408 p. (World Health Organization classification of tumours).

    Google Scholar 

  3. Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844–56.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology. 2005;7(2):134–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Vallée A, Guillevin R, Vallée J-N. Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas. Rev Neurosci. 2018;29(1):71–91.

    Article  PubMed  CAS  Google Scholar 

  6. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–5.

    Article  CAS  PubMed  Google Scholar 

  7. Haddad SF, Moore SA, Schelper RL, Goeken JA. Vascular smooth muscle hyperplasia underlies the formation of glomeruloid vascular structures of glioblastoma multiforme. J Neuropathol Exp Neurol. 1992;51(5):488–92.

    Article  CAS  PubMed  Google Scholar 

  8. Nagashima T, Hoshino T, Cho KG. Proliferative potential of vascular components in human glioblastoma multiforme. Acta Neuropathol. 1987;73(3):301–5.

    Article  CAS  PubMed  Google Scholar 

  9. Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG. Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget. 2012;3(1):98–106.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Takeuchi H, Hashimoto N, Kitai R, Kubota T, Kikuta K. Proliferation of vascular smooth muscle cells in glioblastoma multiforme. J Neurosurg. 2010;113(2):218–24.

    Article  PubMed  Google Scholar 

  11. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg. 1988;68(5):698–704.

    Article  CAS  PubMed  Google Scholar 

  12. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer’s structures. Am J Pathol. 2008;173(2):545–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA. Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther. 2019;12(2):82–8.

    Article  PubMed  Google Scholar 

  14. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004;101(10):2318–26.

    Article  PubMed  Google Scholar 

  15. Kalogerak A, Tamiolakis D, Zoi I, Karvela-Kalogeraki I, Karvelas-Kalogerakis M, Segredakis J, et al. FNA Cytology in pediatric small cell glioblastoma. Acta Biomed. 2018;89(2):265–8.

    PubMed  Google Scholar 

  16. Takeuchi H, Kitai R, Hosoda T, Yamada S, Hashimoto N, Kikuta K, et al. Clinicopathologic features of small cell glioblastomas. J Neuro-Oncol. 2016;127(2):337–44.

    Article  CAS  Google Scholar 

  17. Gokden M. If it is not a glioblastoma, then what is it? A differential diagnostic review. Adv Anat Pathol. 2017;24(6):379–91.

    Article  PubMed  Google Scholar 

  18. Joseph NM, Phillips J, Dahiya S, Felicella MM, Tihan T, Brat DJ, et al. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol. 2013;26(3):315–26.

    Article  CAS  PubMed  Google Scholar 

  19. Ishizawa K, Komori T, Shimada S, Hirose T. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol. 2008;27(3):118–28.

    Article  CAS  PubMed  Google Scholar 

  20. Švajdler M, Rychlý B, Mezencev R, Fröhlichová L, Bednárová A, Pataky F, et al. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: an immunohistochemical study of 98 glial tumors. Histol Histopathol. 2016;31(1):95–102.

    PubMed  Google Scholar 

  21. Otero JJ, Rowitch D, Vandenberg S. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neuro-Oncol. 2011;104(2):423–38.

    Article  Google Scholar 

  22. Jin MC, Wu A, Xiang M, Azad TD, Soltys SG, Li G, et al. Prognostic factors and treatment patterns in the management of giant cell glioblastoma. World Neurosurg. 2019;128:e217–24.

    Article  PubMed  Google Scholar 

  23. Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro-Oncology. 2009;11(6):833–41.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Borkar SA, Lakshmiprasad G, Subbarao KC, Sharma MC, Mahapatra AK. Giant cell glioblastoma in the pediatric age group: report of two cases. J Pediatr Neurosci. 2013;8(1):38–40.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Martinez-Diaz H, Kleinschmidt-DeMasters BK, Powell SZ, Yachnis AT. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin. Arch Pathol Lab Med. 2003;127(9):1187–91.

    Article  CAS  PubMed  Google Scholar 

  26. Figarella-Branger D, Bouvier C, Moroch J, Michalak S, Burel-Vandenbos F. Morphological classification of glioblastomas. Neurochirurgie. 2010;56(6):459–63.

    Article  CAS  PubMed  Google Scholar 

  27. Margetts JC, Kalyan-Raman UP. Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure). Cancer. 1989;63(3):524–31.

    Article  CAS  PubMed  Google Scholar 

  28. Feigin IH, Gross SW. Sarcoma arising in glioblastoma of the brain. Am J Pathol. 1955;31(4):633–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Feigin I, Allen LB, Lipkin L, Gross SW. The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation. Cancer. 1958;11(2):264–77.

    Article  CAS  PubMed  Google Scholar 

  30. Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, et al. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol. 1996;55(9):973–81.

    Article  CAS  PubMed  Google Scholar 

  31. Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol. 2000;156(2):425–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, et al. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neuro-Oncol. 2015;125(2):401–10.

    Article  CAS  Google Scholar 

  33. Smith DR, Wu C-C, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, et al. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. J Neuro-Oncol. 2018;137(2):303–11.

    Article  CAS  Google Scholar 

  34. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg. 1998;89(3):425–30.

    Article  CAS  PubMed  Google Scholar 

  35. Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, et al. Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neuro-Oncol. 2010;97(2):257–65.

    Article  Google Scholar 

  36. Morantz RA, Feigin I, Ransohoff J. Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg. 1976;45(4):398–408.

    Article  CAS  PubMed  Google Scholar 

  37. Beaumont TL, Kupsky WJ, Barger GR, Sloan AE. Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J Neuro-Oncol. 2007;83(1):39–46.

    Article  Google Scholar 

  38. Shintaku M, Yoneda H, Hirato J, Nagaishi M, Okabe H. Gliosarcoma with ependymal and PNET-like differentiation. Clin Neuropathol. 2013;32(6):508–14.

    Article  PubMed  Google Scholar 

  39. Yao K, Qi X-L, Mei X, Jiang T. Gliosarcoma with primitive neuroectodermal, osseous, cartilage and adipocyte differentiation: a case report. Int J Clin Exp Pathol. 2015;8(2):2079–84.

    PubMed  PubMed Central  Google Scholar 

  40. McGahan BG, Toop N, Jones D, Kobalka PJ, Palmer J, Elder JB. Gliosarcoma with PNET component mimicking a neuroendocrine carcinoma with initially only PNET and sarcoma components: a case report. 2021 [In Press].

    Google Scholar 

  41. Sugimoto K, Ideguchi M, Kimura T, Kajiwara K, Imoto H, Sadahiro H, et al. Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma. Brain Tumor Pathol. 2016;33(2):137–46.

    Article  CAS  PubMed  Google Scholar 

  42. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685–98.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Broniscer A, Tatevossian RG, Sabin ND, Klimo P, Dalton J, Lee R, et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol. 2014;40(3):327–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    Article  CAS  PubMed  Google Scholar 

  45. Nitta N, Moritani S, Fukami T, Yoshimura Y, Hirai H, Nozaki K. Intraventricular epithelioid glioblastoma: a case report. World Neurosurg. 2018;112:257–63.

    Article  PubMed  Google Scholar 

  46. Rodriguez FJ, Scheithauer BW, Giannini C, Bryant SC, Jenkins RB. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 2008;113(10):2779–89.

    Article  PubMed  Google Scholar 

  47. Tanaka T, Kaijima M, Yonemasu Y, Cepeda C. Spontaneous secondarily generalized seizures induced by a single microinjection of kainic acid into unilateral amygdala in cats. Electroencephalogr Clin Neurophysiol. 1985;61(5):422–9.

    Article  CAS  PubMed  Google Scholar 

  48. Alexandrescu S, Korshunov A, Lai SH, Dabiri S, Patil S, Li R, et al. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas--same entity or first cousins? Brain Pathol. 2016;26(2):215–23.

    Article  CAS  PubMed  Google Scholar 

  49. Furuta T, Miyoshi H, Komaki S, Arakawa F, Morioka M, Ohshima K, et al. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Neuropathology. 2018;38(3):218–27.

    Article  CAS  PubMed  Google Scholar 

  50. Song X, Andrew Allen R, Terence Dunn S, Fung K-M, Farmer P, Gandhi S, et al. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol. 2011;4(7):651–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Kim DG, Lee DY, Paek SH, Chi JG, Choe G, Jung H-W. Supratentorial primitive neuroectodermal tumors in adults. J Neuro-Oncol. 2002;60(1):43–52.

    Article  Google Scholar 

  52. Prelaj A, Rebuzzi SE, Caffarena G, Giròn Berrìos JR, Pecorari S, Fusto C, et al. Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature. Oncol Lett. 2018;15(5):6641–7.

    PubMed  PubMed Central  Google Scholar 

  53. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T. A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature. J Neuro-Oncol. 2008;86(2):217–24.

    Article  Google Scholar 

  54. Kouyialis AT, Boviatsis EI, Karampelas IK, Korfias S, Korkolopoulou P, Sakas DE. Primitive supratentorial neuroectodermal tumor in an adult. J Clin Neurosci. 2005;12(4):492–5.

    Article  CAS  PubMed  Google Scholar 

  55. Xu G, Li JY. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component. J Neuro-Oncol. 2018;136(3):445–52.

    Article  CAS  Google Scholar 

  56. Vollmer K, Pantazis G, Añon J, Roelcke U, Schwyzer L. Spinal metastases of supratentorial glioblastoma with primitive neuronal component. World Neurosurg X. 2019;2:100019.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Yoshida Y, Ide M, Fujimaki H, Matsumura N, Nobusawa S, Ikota H, et al. Gliosarcoma with primitive neuronal, chondroid, osteoid and ependymal elements. Neuropathology. 2018;38(4):392–99.

    Google Scholar 

  58. Martins DC, Malheiros SM, Santiago LH, Stávale JN. Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neuro-Oncol. 2006;80(1):49–55.

    Article  CAS  Google Scholar 

  59. Heesters M, Molenaar W, Go GK. Radiotherapy in supratentorial gliomas. A study of 821 cases. Strahlenther Onkol. 2003;179(9):606–14.

    Article  PubMed  Google Scholar 

  60. Krouwer HG, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 1991;74(3):399–406.

    Article  CAS  PubMed  Google Scholar 

  61. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol. 1998;95(6):559–64.

    Article  CAS  PubMed  Google Scholar 

  62. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Investig. 1997;76(2):277–84.

    CAS  PubMed  Google Scholar 

  63. Tihan T, Vohra P, Berger MS, Keles GE. Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neuro-Oncol. 2006;76(2):175–83.

    Article  Google Scholar 

  64. Yang HJ, Kim JE, Paek SH, Chi JG, Jung H-W, Kim DG. The significance of gemistocytes in astrocytoma. Acta Neurochir. 2003;145(12):1097–103; discussion 1103.

    Article  CAS  PubMed  Google Scholar 

  65. Brat DJ, Scheithauer BW, Medina-Flores R, Rosenblum MK, Burger PC. Infiltrative astrocytomas with granular cell features (granular cell astrocytomas): a study of histopathologic features, grading, and outcome. Am J Surg Pathol. 2002;26(6):750–7.

    Article  PubMed  Google Scholar 

  66. Vizcaino MA, Palsgrove DN, Yuan M, Giannini C, Cabrera-Aldana EE, Pallavajjala A, et al. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Brain Pathol. 2019;29(2):193–204.

    Article  CAS  PubMed  Google Scholar 

  67. Chorny JA, Evans LC, Kleinschmidt-DeMasters BK. Cerebral granular cell astrocytomas: a Mib-1, bcl-2, and telomerase study. Clin Neuropathol. 2000;19(4):170–9.

    CAS  PubMed  Google Scholar 

  68. Caporalini C, Buccoliero AM, Scoccianti S, Moscardi S, Simoni A, Pansini L, et al. Granular cell astrocytoma: report of a case and review of the literature. Clin Neuropathol. 2016;35(4):186–93.

    Article  PubMed  Google Scholar 

  69. Schittenhelm J, Psaras T. Glioblastoma with granular cell astrocytoma features: a case report and literature review. Clin Neuropathol. 2010;29(5):323–9.

    Article  CAS  PubMed  Google Scholar 

  70. Porter BF, Summers BA, Leland MM, Hubbard GB. Glioblastoma multiforme in three baboons (Papio spp). Vet Pathol. 2004;41(4):424–8.

    Article  CAS  PubMed  Google Scholar 

  71. Roncaroli F, Scheithauer BW, Laeng RH, Cenacchi G, Abell-Aleff P, Moschopulos M. Lipomatous meningioma: a clinicopathologic study of 18 cases with special reference to the issue of metaplasia. Am J Surg Pathol. 2001;25(6):769–75.

    Article  CAS  PubMed  Google Scholar 

  72. Giangaspero F, Kaulich K, Cenacchi G, Cerasoli S, Lerch K-D, Breu H, et al. Lipoastrocytoma: a rare low-grade astrocytoma variant of pediatric age. Acta Neuropathol. 2002;103(2):152–6.

    Article  CAS  PubMed  Google Scholar 

  73. Garg N, Gaur K, Batra VV, Jagetia A. Pilocytic astrocytoma with adipocytic differentiation: a rare histological variation. J Pediatr Neurosci. 2018;13(2):260–3.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Aker FV, Ozkara S, Eren P, Peker O, Armağan S, Hakan T. Cerebellar liponeurocytoma/lipidized medulloblastoma. J Neuro-Oncol. 2005;71(1):53–9.

    Article  Google Scholar 

  75. Hamlat A, Le Strat A, Guegan Y, Ben-Hassel M, Saikali S. Cerebellar pleomorphic xanthoastrocytoma: case report and literature review. Surg Neurol. 2007;68(1):89–94; discussion 94–95.

    Article  PubMed  Google Scholar 

  76. Rickert CH, Riemenschneider MJ, Schachenmayr W, Richter H-P, Bockhorn J, Reifenberger G, et al. Glioblastoma with adipocyte-like tumor cell differentiation--histological and molecular features of a rare differentiation pattern. Brain Pathol. 2009;19(3):431–8.

    Article  CAS  PubMed  Google Scholar 

  77. Gupta K, Kalra I, Salunke P, Vasishta RK. Lipidized glioblastoma: a rare differentiation pattern. Neuropathology. 2011;31(1):93–7.

    Article  PubMed  Google Scholar 

  78. Gessi M, Gielen GH, Denkhaus D, Antonelli M, Giangaspero F, Zur Mühlen A, et al. Molecular heterogeneity characterizes glioblastoma with lipoblast/adipocyte-like cytology. Virchows Arch. 2015;467(1):105–9.

    Article  CAS  PubMed  Google Scholar 

  79. Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer. 2012;118(22):5608–13.

    Article  PubMed  Google Scholar 

  80. Fukuda T, Yasumichi K, Suzuki T. Immunohistochemistry of gliosarcoma with liposarcomatous differentiation. Pathol Int. 2008;58(6):396–401.

    Article  PubMed  Google Scholar 

  81. Kelly MF, Parker PA, Scott RN. The application of neural networks to myoelectric signal analysis: a preliminary study. IEEE Trans Biomed Eng. 1990;37(3):221–30.

    Article  CAS  PubMed  Google Scholar 

  82. Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, et al. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro-Oncology. 2013;15(12):1635–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wang Y, Li S, Chen L, You G, Bao Z, Yan W, et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-Oncology. 2012;14(4):518–25.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006;65(9):846–54.

    Article  CAS  PubMed  Google Scholar 

  85. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001;101(4):311–20.

    Article  CAS  PubMed  Google Scholar 

  86. Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, et al. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol. 2013;23(4):454–61.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Jie W, Bai J, Li B. An extracranial metastasis of glioblastoma mimicking mucoepidermoid carcinoma. World Neurosurg. 2018;116:352–6.

    Article  PubMed  Google Scholar 

  88. Kishikawa M, Tsuda N, Fujii H, Nishimori I, Yokoyama H, Kihara M. Glioblastoma with sarcomatous component associated with myxoid change. A histochemical, immunohistochemical and electron microscopic study. Acta Neuropathol. 1986;70(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  89. Kepes JJ. Astrocytomas: old and newly recognized variants, their spectrum of morphology and antigen expression. Can J Neurol Sci. 1987;14(2):109–21.

    Article  CAS  PubMed  Google Scholar 

  90. Miyata S, Sugimoto T, Kodama T, Akiyama Y, Nakano S, Wakisaka S, et al. Adenoid glioblastoma arising in a patient with neurofibromatosis type-1. Pathol Int. 2005;55(6):348–52.

    Article  PubMed  Google Scholar 

  91. Kepes JJ, Fulling KH, Garcia JH. The clinical significance of “adenoid” formations of neoplastic astrocytes, imitating metastatic carcinoma, in gliosarcomas. A review of five cases. Clin Neuropathol. 1982;1(4):139–50.

    CAS  PubMed  Google Scholar 

  92. Mørk SJ, Rubinstein LJ, Kepes JJ, Perentes E, Uphoff DF. Patterns of epithelial metaplasia in malignant gliomas. II. Squamous differentiation of epithelial-like formations in gliosarcomas and glioblastomas. J Neuropathol Exp Neurol. 1988;47(2):101–18.

    Article  PubMed  Google Scholar 

  93. Lopez Fernandez A. Osteoarticular tuberculosis in the child. Acta Pediatr Esp. 1956;14(162):486–7.

    CAS  PubMed  Google Scholar 

  94. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 [cited 2020 Aug 16]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK470003/.

  95. Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro-Oncology. 2009;11(4):403–13.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P-L, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892–9.

    Article  CAS  PubMed  Google Scholar 

  97. Liu M, Thakkar JP, Garcia CR, Dolecek TA, Wagner LM, Dressler EVM, et al. National cancer database analysis of outcomes in pediatric glioblastoma. Cancer Med. 2018;7(4):1151–9.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-Oncology. 2009;11(3):274–80.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Das KK, Mehrotra A, Nair AP, Kumar S, Srivastava AK, Sahu RN, et al. Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome. Childs Nerv Syst. 2012;28(12):2055–62.

    Article  PubMed  Google Scholar 

  100. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(Suppl_1):iv1–96.

    Google Scholar 

  101. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–74.

    Article  PubMed  Google Scholar 

  104. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–7.

    Article  CAS  PubMed  Google Scholar 

  105. Frappaz D, Ricci AC, Kohler R, Bret P, Mottolese C. Diffuse brain stem tumor in an adolescent with multiple enchondromatosis (Ollier’s disease). Childs Nerv Syst. 1999;15(5):222–5.

    Article  CAS  PubMed  Google Scholar 

  106. Haliloglu G, Jobard F, Oguz KK, Anlar B, Akalan N, Coskun T, et al. L-2-hydroxyglutaric aciduria and brain tumors in children with mutations in the L2HGDH gene: neuroimaging findings. Neuropediatrics. 2008;39(2):119–22.

    Article  CAS  PubMed  Google Scholar 

  107. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7):896–913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–32.

    Article  CAS  PubMed  Google Scholar 

  109. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.

    Article  PubMed  Google Scholar 

  110. Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci. 2012;32(41):14087–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, USA, July 13–15, 1987. Neurofibromatosis. 1988;1(3):172–8.

    Google Scholar 

  112. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151(1):33–40.

    Article  CAS  PubMed  Google Scholar 

  113. Gutmann DH, Rasmussen SA, Wolkenstein P, MacCollin MM, Guha A, Inskip PD, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology. 2002;59(5):759–61.

    Article  CAS  PubMed  Google Scholar 

  114. Rodriguez FJ, Perry A, Gutmann DH, O’Neill BP, Leonard J, Bryant S, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008;67(3):240–9.

    Article  PubMed  Google Scholar 

  115. Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, et al. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010;54(7):890–6.

    PubMed  Google Scholar 

  116. Fortunato JT, Reys B, Singh P, Pan E. Brainstem glioblastoma multiforme in a patient with NF1. Anticancer Res. 2018;38(8):4897–900.

    Article  PubMed  Google Scholar 

  117. Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, et al. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol. 2018;35(1):10–8.

    Article  CAS  PubMed  Google Scholar 

  118. Taraszewska A, Bogucki J, Powała A, Matyja E. Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis type 1. Clin Neuropathol. 2013;32(1):58–65.

    PubMed  Google Scholar 

  119. Takahashi Y, Makino K, Nakamura H, Hide T, Yano S, Kamada H, et al. Clinical characteristics and pathogenesis of cerebellar glioblastoma. Mol Med Rep. 2014;10(5):2383–8.

    Article  CAS  PubMed  Google Scholar 

  120. Kroh H, Matyja E, Marchel A, Bojarski P. Heavily lipidized, calcified giant cell glioblastoma in an 8-year-old patient, associated with neurofibromatosis type 1 (NF1): report of a case with long-term survival. Clin Neuropathol. 2004;23(6):286–91.

    CAS  PubMed  Google Scholar 

  121. Durno CA, Sherman PM, Aronson M, Malkin D, Hawkins C, Bakry D, et al. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur J Cancer. 2015;51(8):977–83.

    Article  CAS  PubMed  Google Scholar 

  122. Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50(5):987–96.

    Article  PubMed  Google Scholar 

  123. Wimmer K, Kratz CP, Vasen HFA, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD” (C4CMMRD). J Med Genet. 2014;51(6):355–65.

    Article  CAS  PubMed  Google Scholar 

  124. Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology. 2015;17(10):1356–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Leoz ML, Carballal S, Moreira L, Ocaña T, Balaguer F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet. 2015;8:95–107.

    PubMed  PubMed Central  Google Scholar 

  126. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233–8.

    Article  CAS  PubMed  Google Scholar 

  127. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995;56(3):608–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997;57(15):3245–52.

    CAS  PubMed  Google Scholar 

  129. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–31.

    Article  CAS  PubMed  Google Scholar 

  130. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10(9):1054–72.

    Article  CAS  PubMed  Google Scholar 

  131. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.

    CAS  PubMed  Google Scholar 

  132. Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150(1):1–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. 2009;117(6):653–6.

    Article  CAS  PubMed  Google Scholar 

  134. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Topçu M, Jobard F, Halliez S, Coskun T, Yalçinkayal C, Gerceker FO, et al. L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet. 2004;13(22):2803–11.

    Article  PubMed  Google Scholar 

  136. Rzem R, Van Schaftingen E, Veiga-da-Cunha M. The gene mutated in l-2-hydroxyglutaric aciduria encodes l-2-hydroxyglutarate dehydrogenase. Biochimie. 2006;88(1):113–6.

    Article  CAS  PubMed  Google Scholar 

  137. Patay Z, Mills JC, Löbel U, Lambert A, Sablauer A, Ellison DW. Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. AJNR Am J Neuroradiol. 2012;33(5):940–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Moroni I, Bugiani M, D’Incerti L, Maccagnano C, Rimoldi M, Bissola L, et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology. 2004;62(10):1882–4.

    Article  CAS  PubMed  Google Scholar 

  139. Wanders RJ, Vilarinho L, Hartung HP, Hoffmann GF, Mooijer PA, Jansen GA, et al. L-2-Hydroxyglutaric aciduria: normal L-2-hydroxyglutarate dehydrogenase activity in liver from two new patients. J Inherit Metab Dis. 1997;20(5):725–6.

    Article  CAS  PubMed  Google Scholar 

  140. Tan AP, Mankad K. Intraventricular glioblastoma multiforme in a child with L2-hydroxyglutaric aciduria. World Neurosurg. 2018;110:288–90.

    Article  PubMed  Google Scholar 

  141. Pansuriya TC, van Eijk R, d’Adamo P, van Ruler MAJH, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–43.

    Article  CAS  PubMed  Google Scholar 

  143. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet. 2002;30(3):306–10.

    Article  PubMed  Google Scholar 

  144. Chang S, Prados MD. Identical twins with Ollier’s disease and intracranial gliomas: case report. Neurosurgery. 1994;34(5):903–6; discussion 906.

    CAS  PubMed  Google Scholar 

  145. Ranger A, Szymczak A, Hammond RR, Zelcer S. Pediatric thalamic glioblastoma associated with Ollier disease (multiple enchondromatosis): a rare case of concurrence. J Neurosurg Pediatr. 2009;4(4):363–7.

    Article  PubMed  Google Scholar 

  146. Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, et al. Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathol Commun. 2016;4:31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ohio State University Medical Center, Department of Neurology/Neuro-oncology, Columbus, OH, USA

    Appaji Rayi

  2. Charleston Area Medical Center, Department of Neurology, Charleston, WV, USA

    Appaji Rayi

  3. The Ohio State University Medical Center, Department of Pathology and Laboratory Medicine, Columbus, OH, USA

    Peter J. Kobalka

Authors
  1. Appaji Rayi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Kobalka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Kobalka .

Editor information

Editors and Affiliations

  1. Neuropathology, The Ohio State University, Columbus, OH, USA

    José Javier Otero

  2. Radiation Oncology, The Ohio State University, Columbus, OH, USA

    Aline Paixao Becker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rayi, A., Kobalka, P.J. (2021). Histopathology of Adult and Pediatric Glioblastoma. In: Otero, J.J., Becker, A.P. (eds) Precision Molecular Pathology of Glioblastoma. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-030-69170-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69170-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-69169-1

  • Online ISBN: 978-3-030-69170-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation